心脏性休克中的病理生理血管扩张及其对死亡率的影响
Miguel A Chavez1, McHale Anderson1, Christos P Kyriakopoulos1
1Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City (M.A.C., M.A., C.P.K., M.S., E.D., I.T., J.L., B.K., J.G., M.G., C.H.S., J.E.T., J.C.F., S.G.D., T.C.H.).
Circulation. Heart failure
|July 25, 2024
概括
血管扩张在心脏性休克 (CS) 中很常见,并增加死亡风险. 通过低系统性血管阻力 (SVR) 或压力反应识别血管扩张对于患者的治疗结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 血液动力学 血液动力学
背景情况:
- 心脏性休克 (CS) 具有很高的死亡率,通常由血管扩张加剧,超过心脏输出不足.
- 了解严重的CS血管扩张的患病率和影响对于改善患者存活率至关重要.
研究的目的:
- 调查心脏性休克患者血管扩张的发生情况.
- 确定CS患者血管扩张和死亡率之间的关联.
主要方法:
- 对713名CS患者 (B-E阶段) 的回顾性分析,没有败血症或最近的心脏手术.
- 血管扩张是由低系统血管阻力 (SVR),高上腺素等效剂量或压力对SVR反应减弱所定义的.
- 通过多变量调整的Cox模型评估14天死亡率,通过spline模型确定SVR值.
主要成果:
- 38%的CS患者表现出血管扩张,14天死亡率为28%.
- 较低的SVR (<800dynes•s•cm-5),较高的压力剂量和压力响应的减弱独立地与死亡率的增加有关.
- 压力反应减弱几乎使死亡风险增加了一倍 (aHR,1.74).
结论:
- 病理生理血管扩张是CS的重要和普遍因素,独立增加死亡风险.
- 对CS血管扩张的关键指标包括SVR<800dyn•s•cm-5,升高的压力要求,或降低的压力反应.
- 对CS相关血管扩张的机制和治疗策略进行进一步研究是有必要的.
相关概念视频
01:24Blood Pressure Imbalances and Circulatory Shock
765
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
765
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
333
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
01:23Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K